Calvin Hawe

Calvin joined Octant as a Chemistry Apprentice on the high-throughput synthesis team and is currently a Research Associate contributing to our drug discovery efforts and the OpenADMET consortium. He graduated from Notre Dame with a B.S. in biochemistry, concentrating in neuroscience and minoring in patient advocacy. In the Serianni Lab, he synthesized carbohydrates and glycoconjugates to study the three-dimensional structure and conformation of these biomolecules using NMR.

Calvin has prior experience in the biopharmaceutical industry developing large-molecule analytical methods at AstraZeneca and Merck. At AstraZeneca/MedImmune, he designed a two-dimensional HPLC method that accurately characterizes mAbs and ADCs in high concentrations of a micelle-forming surfactant excipient. At Merck Research Laboratories, he developed novel high-throughput CE-SDS methods for a broad range of next-generation therapeutic proteins, including fusion proteins, bispecific engagers, Fc-peptide conjugates, and trispecific antibodies (in addition to traditional mAbs and ADCs).

Outside the lab, you can find him sewing for fun and biking around the Bay.

PAPERS
Hawe, C.; Tunink, K.; Wenger, D. “Krabbe Disease.” National Organization for Rare Disorders 2024, https://rarediseases.org/rare-diseases/leukodystrophy-krabbes/

Arruebarrena, M.A.; Hawe, C.T.; Lee, Y.M.; Branco, R.C. “Mechanisms of Cadmium Neurotoxicity.” International Journal of Molecular Sciences 2023, 24, 16558. https://doi.org/10.3390/ijms242316558

‍